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Abstract. This study was designed to investigate whether a non-protein nanostructured lipid carrier
(NLC) resembling high-density lipoprotein (HDL) could deliver a hydrophobic anti-atherogenic drug,
lovastatin, to foam cells. Lovastatin-loaded NLC (LT-NLC) was prepared by a nanoprecipitation/solvent
diffusion method. The LT-NLC-apoprotein (LT-NLC-apo) was prepared by incubating LT-NLC with
native HDL. The physicochemical parameters of LT-NLC were characterized in terms of particle size,
zeta potential, morphology, entrapment efﬁciency, and crystallization behavior. Targeting behavior and
mechanism were demonstrated by the incubation of LT-NLC-apo with a RAW 264.7 macrophage-derived
foam cell model in the presence or absence of very-low-density lipoprotein (VLDL) and lipase. The
results showed that LT-NLC was solid spherical or oval in shape with an average diameter of 13.8±
2.2 nm, zeta potential of −29.3±0.2 mV and entrapment efﬁciency of 96.2±1.3%. Phagocytosis studies
showed that uptake of LT-NLC-apo by macrophages was signiﬁcantly lower than LT-NLC (p<0.01),
suggesting that LT-NLC-apo could possibly escape recognition from macrophages in vivo. The uptake
was increased twofold when LT-NLC-apo was incubated with transfected foam cells containing VLDL
and lipase. These results indicated that non-protein NLC resembling HDL could be a useful tool to
deliver lipophilic anti-atherogenic drugs to foam cells, and that uptake could be enhanced by the VLDL
receptor pathway.
KEY WORDS: atherosclerosis; foam cell targeting; high-density lipoprotein; lovastatin; nanostructured
lipid carrier.
INTRODUCTION
Atherosclerosis is a chronic inﬂammatory disease of the
blood vessels characterized by the presence of many lipid-
laden “foam cells” (macrophages with ingested oxidized low-
density lipoprotein) (1,2). Studies on atherosclerotic lesions
showed that foam cells, the main pathological cells of the
atherosclerosis plaque, have up-regulated scavenger receptors
(SR) and very-low-density lipoprotein (VLDL) receptors
(3,4). Thus, it appears that these receptors are potential
molecular targets for the selective delivery of anti-athero-
sclerosis agents to foam cells.
Native high-density lipoprotein (HDL) is a heterogeneous
class of plasma lipoproteins that have a density between
1.063 and 1.21 g/ml and a Stoke's diameter of 5–17 nm (5).
Spherical HDL particles have a hydrophobic core that is
surrounded by a monolayer of phospholipids, unesteriﬁed
cholesterol, and apoproteins. The major apoprotein of
HDL is apoA-I, although other apoproteins may also be
present (6). ApoA-I mediates the cellular uptake of HDL
cholesterol via a speciﬁch i g h - a f ﬁnity receptor pathway
such as SR class BI (SR-BI) (7). In addition, the
cholesteryl ester can be transferred from HDL to VLDL
via cholesteryl ester transfer protein (CETP) (8). VLDL is
the major ligand for the VLDL receptor, so the cholesteryl
ester in HDL can be transported to the cells through the
indirect pathway. The above two pathways could be useful
for the delivery and concentration of drugs into the foam
cells which are capable of expressing SR-BI and VLDL
receptors.
In the last few decades, reconstituted HDL (rHDL) has
been investigated as a drug delivery system for cells express-
ing the HDL receptor since its hydrophobic core has the
possibility of incorporating lipophilic drugs (9). Drugs have
been either directly loaded onto rHDL (10), or used as the
lipid core of rHDL (11). These HDL-like nanoparticles offer
advantages including (1) biodegradability; (2) protein com-
ponents that are endogenous and do not trigger immuno-
reactions; (3) the particles are not recognized by the
reticuloendothelial system (RES); and (4) their direct anti-
atherogenic effects (12). Furthermore, HDL-like particles are
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drug payload (13).
The main limitation for the therapeutic application of
rHDL is the necessity to isolate HDL apolipoproteins from
human serum, or to resort to cell expression systems that
secrete recombinant human apoA-I (14,15). To solve this
problem, previous studies in our laboratory have succeeded
in preparing protein-free Tanshinone IIA nanostructured
lipid carriers (NLC) with HDL components, and demonstra-
ted that NLC can acquire the main apolipoproteins in the
native HDL by in vitro incubation and can turn endogenous
(16). However, the mechanism and targeting ability of the
resulting product to foam cells has not been evaluated. So far,
the use of rHDL for delivering anti-atherosclerosis drugs to
foam cells has not been reported in the literature.
Lovastatin (LT), a highly lipophilic drug (log P=4.3)
isolated from a fungus of Aspergillus terreus, is an effective
anti-atherosclerosis agent which can slow the progression of
atherosclerosis through their lipid-lowering effects and non-
lipid-lowering effects which involve improving or restoring
endothelial function, decreasing oxidative stress and vascular
inﬂammation as well as enhancing the stability of athero-
sclerotic plaques (17). However, LT exhibits poor bioavail-
ability because of its poor water solubility (0.4×10
−3 mg/mL)
and short half-life (1–2 h). Therefore, a formulation which
could deliver LT more speciﬁcally to the foam cells presented
in the artery intima, preferably with longer half-life would be
highly desirable for treatment of atherosclerosis.
The aim of the present work was to develop an HDL
drug delivery system resembling native spherical HDL
particles with the function of targeting the drug, lovastatin,
to foam cells on the atherosclerosis plaque. In addition, LT
may also act as a model lipiphilic drug for this novel targeting
delivery system for treatment of atherosclerosis after intra-
venous administration. LT-loaded NLC was prepared with
properties resembling the lipid components of HDL. In vitro
phagocytosis by macrophages and foam cells were used as
reproducible models (18) to study the potential site-speciﬁc
targeting effect of lovastatin-loaded NLC (LT-NLC)-apo on
the atherosclerosis plaque.
MATERIALS AND METHODS
Materials
Lovastatin was kindly donated by Jiangsu Yangze River
Pharmacy Company (Taizhou, Jiangsu, China). Lipoid S 100
was obtained from Lipoid GmbH (Ludwigshafen, Germany).
Cholesterolwas purchased from Sigma–AldrichChemieGmbH
(Steinheim, Germany). Cholesteryl oleate was supplied by Alfa
Aesar/Johnson Matthey Co. Ltd (Lancashire, UK). Glycerol
trioleate was a product of Tokyo Kasei Kogyo Co. Ltd. (Tokyo,
Japan). Human plasma was supplied from Nanjing Red Cross
(Nanjing, Jiangsu, China). Sephadex G50 was purchased from
Pharmacia (Sweden). The mouse macrophage RAW264.7 cell
line was obtained from American Type Culture Collection
(Maryland, USA). Oxidized low-density lipoprotein of human
(2 mg/ml) was purchased from Yuanyuan biotechnology
(Guangzhou, Guangdong, China). Lipid-free BSA (A2000)
was supplied by Applygen Technologies (Beijing, China).
Pancrelipase was obtained from Sigma–Aldrich (L3126, USA).
β-mercaptoethanol were purchased from Sigma–Aldrich(Mil-
waukee, USA). All reagents were of analytical grade and
methanol of chromatographic grade.
Isolation of VLDL and HDL from Human Plasma
Plasma was obtained from normal human volunteers
who had fasted overnight. The method for isolation of VLDL
and HDL was based on the sequential ﬂotation ultracentri-
fugation procedure described by Schumaker et al.( 19). One
hundred milliliters of plasma was adjusted to 122.5 ml with
solid NaCl so that the background salt density was 1.019 g/ml,
then centrifuged in 12 screw-top, thick-walled polycarbonate
ultracentrifuge tubes (polyallomer Bell-top; Beckman) at
124,800×g, 10°C for 18 h using a Beckman Optima LE-80K
Centrifuge.
The VLDL was removed in the ﬁrst centrifugation above
the background solution. The background solutions at the
bottom were pooled to obtain LDL and HDL. The LDL was
isolated and the density was adjusted to 1.063 g/ml by adding
KBr before it was re-centrifuged at 195,000×g at 10°C for
24 h. After the LDL was removed, HDL was isolated with the
same centrifuge procedure as LDL after the density of the
background salt solution was adjusted to 1.21 g/ml.
The isolated VLDL and HDL fractions were dialyzed in
the dark at 4°C for 24 h against four changes of 2 L of 0.15 M
NaCl, 0.004 M Na2HPO4, and 0.903 mM EDTA, ﬁltered
through a 0.22-μm ﬁlter. Lipoprotein purity was assessed
using a 4% sodium dedocyl sulfate (SDS)-polyacrylamide gel
electrophoresis and their concentration was normally deter-
mined by the Lowry method (20). The materials were stored
at 4°C in sterile bottles for formulation and evaluation.
Preparation of LT-NLC
LT-NLC was prepared by a nanoprecipitation/solvent
diffusion method. This modiﬁed method was based on a
preliminary study (16) to optimize the drug incorporation into
NLC. Brieﬂy, the lipid mixture (cholesteryl oleate, glycerol
trioleate, soybean lecithin, and cholesterol) and lovastatin
were dissolved in 8 ml acetone and 2 ml ethanol by sonication
(DL-720, Shanghai, China). The aqueous phase containing
0.1 M KC1, 1 mM EDTA and 0.01 M Tris–HCl, pH 8.0 in
double-distilled water (30 ml), was heated to 65°C. After-
wards, the organic phase was injected slowly into the aqueous
phase at the same temperature under constant magnetic
agitation and a semi-transparent pre-emulsion was obtained.
The pre-emulsion was sonicated using an Ultrahomogenizer
(JY 92II, Ningbo, China) under 300 W for 200 s before it was
transferred to a rotary evaporator to remove the organic
solvent at 55°C under reduced pressure. The prepared LT-
NLC nanosuspension was ﬁltered through 0.22-μm ﬁlters
after cooling down to room temperature. The LT-NLC was
stored at 4°C before use.
Formation of LT-NLC-apo
LT-NLC suspension (6 ml) was incubated with 4 ml of
the above isolated native HDL for 4 h on a shaking bed
(SHZ-82A, Jintan, China, 120 rpm, 37°C). After incubation,
solid KBr was added to adjust the density of incubated
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ultracentrifugation at 195,000×g at 10°C for 24 h. After
ultracentrifugation, free LT-NLC which ﬂoated above the
background solution was removed by aspiration with a
needle. Then the LT-NLC acquiring apolipoproteins (LT-
NLC-apo) in the liquid layer at the bottom of the tube, were
recovered and puriﬁed by dialyzing against four changes of
2 L of 0.01 M Tris–HCl buffer, containing 0.15 M NaCl and
1 mM EDTA (16,21).
Measurement of Size and Zeta Potential
The size and zeta potential of LT-NLC and LT-NLC-apo
were measured by photon correlation spectroscopy (PCS) using
a Zetasizer 3000 HSA (Malvern, UK). Samples were diluted
ﬁve times with the aqueous phase used in formulation for the
measurements. Zeta potential measurements were carried out
at 25°C, and the electric ﬁeld strength was around 23.2 V/cm.
Determination of Entrapment Efficiency
LT-NLC encapsulation efﬁciency was calculated after
separation of the non-entrapped drug using the mini-column
centrifugation method (22,23). A suitable amount of Sepha-
dex G50 was swollen in distilled water at room temperature
for at least 5 h and stored at 4°C. To prepare the mini-
columns, absorbent cotton was inserted in the bottom of the
5-ml plastic syringes which were then ﬁlled with gel. The
column was inserted into a test tube. Excessive distilled water
was centrifuged off at 2000 rpm for 6 s, and 400 μl of the LT-
NLC suspensions were added dropwise to the center of the
column, followed by 5 min centrifugation at 1000 rpm. To
wash the mini-column, 400 μl distilled water was added and
centrifugation repeated. Then the LT-NLC was forced
through the column into a test tube while the free LT was
quantitatively retained in the Sephadex. LT-NLC can be
recovered from the ﬁrst and second stages of centrifugation.
The amount of the drug entrapped in the NLC and the
total drug were determined by HPLC (Shimadzu LC-10A,
Kyoto, Japan) equipped with an ultraviolet (UV) detector
operated at 238 nm and a Shim-pack VP-ODS (150×4.6 mm)
column. The mobile phase was methanol/water (76:24); the
ﬂow rate was kept at 1 ml/min; the column temperature was
30±0.2°C. Drug and excipients were validated to have no
interference with each other. Samples were dissolved diluted
with absolute ethanol. The entrapment efﬁciency (EE) for LT
was calculated with the following formula:
EE % ðÞ ¼ C=C0   100 ð1Þ
where EE is the drug entrapment efﬁciency, C is the amount
of drug encapsulated, and C0 is the total amount of drug in
the LT-NLC suspension.
Stability of LT-NLC and LT-NLC-apo
The physical stability of the formulations was investi-
gated. Three batches of LT-NLC were stored at 25°C and 4°C
in the dark for 1 month. The LT-NLC-apo was only stored at
4°C. Their appearance, particle size, and zeta potential
against storage time were evaluated.
Transmission Electron Microscopy
The microstructures of LT-NLC-apo and LT-NLC were
examined by transmission electron microscopy (TEM; H-
7650, Hitachi, Japan) using a negative stain method. Samples
were diluted 20 times with aqueous phase. A drop of each
sample was applied to a copper grid coated with carbon ﬁlm
and air dried; 2% (w/v) phosphotungstic acid solution was
then dropped onto the grids. After being negatively stained
and air dried under room temperature, the samples were
ready for TEM investigation. The analysis procedure was
based on the instruction for TEM H-7650. The accelerate
voltage was 80 kV and the magniﬁcation was 20.0 K for LT-
NLC and 25.0 K for LT-NLC-apo.
Characterization by Differential Scanning Calorimetry
Thermograms were recorded with a differential scanning
calorimeter (DSC 204, NETZSCH, Germany). For DSC
measurements, standard aluminum pans with appropriate
amount of samples were tightly sealed and an empty pan
was used as reference. A scan rate of 10°C/min was employed
in the temperature range of 25–300°C. The samples used for
these analyses were as follows.
(1) Lovastatin; (2) lipid mixtures (LM) of phospholipids,
cholesteryl oleate, cholesterol, and glycerol trioleate; (3)
physical mixtures (PM) of LT, phospholipids, cholesteryl
oleate, and glycerol trioleate at a similar weight ratio to LT-
NLC formulation; (4) lyophilized samples of LT-NLC; and (5)
LT solid lipid nanoparticles (LT-SLN) were prepared with all
excipients except liquid lipid glycerol trioleate and which
were frozen at −52°C for 8 h.
LT-NLC and LT-SLN samples were freeze dried at −52°C
and a pressure of 7.5 mmHg for 40 h. The LT-NLC and LT-SLN
powder was collected and stored at 4°C before analysis.
Cell Culture
At present, THP-1, U937, and RAW264.7 have com-
monly been used to establish foam cells models. Compared
with the other two cells, RAW 264.7 cells were stable, easy to
culture and adherent, and have been employed by a large
number of studies for investigation of the foam cells
formation pathway, the mechanism of anti-inﬂammatory
drugs and inﬂammatory signaling pathways (24). In this
study, the mouse macrophage cell line RAW 264.7 was
routinely cultured in Dulbecco's Modiﬁed Eagle Medium
(DMEM; Sigma, St. Louis, USA) containing 10% fetal
bovine serum with penicillin (100 U/mL) and streptomycin
(100 pg/mL) at 37°C in a humidiﬁed, 5% CO2 incubator. The
medium was changed every 3 days. After trypsinisation and
counting, 1×10
5 macrophages per well were cultured in lipid-
depleted medium in 24-well plates overnight. After that, the
foam cell model was established by treating with oxidized
low-density lipoproteins (ox-LDL, 100 μg/ml) for 24 h (25).
The normal RAW 264.7 macrophage cells that were not
treated with ox-LDL were used for non-speciﬁc phagocytosis
study. The formation of foam cells was conﬁrmed by an Oil-
Red O Staining method and HPLC determination of choles-
terol extracted from the cells (26).
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The procedure for CETP plasmid ampliﬁcation was modi-
ﬁed from the method previously described by Lederberg et al.
(27).CETPplasmidwas dissolved in 20~50 μl TE buffer (10 Mm
Tris-Cl, pH 8.0, 50 mM EDTA, pH 8.0) in a 50~60°C water bath.
Then 1 μl of the plasmid was added to 20 μl Escherichia coli DH-
5α competent cells which were thawed on ice for 15 min. The
mixture was further incubated for 30 min on ice. Competent cells
werethen subjected to heat shock in a water bath at 42°Cfor 45 s
and a further 2-min incubation on ice. Then 400 μlo fL u r i a -
Bertani(LB) broth atroomtemperaturewas immediately added
tothebacterialcellsandincubatedina37°Cshakerincubatorfor
1hallowingtheexpressionofplasmidencodedgenes. Afterthat,
100 μl samples were spread on an LB agar plate containing
ampicillin and incubated at 37°C for 12~16 h to allow colonies to
form. Thereafter, 5 ml of LB medium containing ampicillin with
as i n g l ec o l o n yo fE. coli was inoculated and grown in a 37°C
shaker incubator (200 rpm) for 24 h. The CETP plasmids were
puriﬁed following the procedure of Genomic DNA Kit (Tiangen
Biotech). The concentration of the DNA was measured by
spetrophotometry (DU-650, Beckman).
Transfection of Foam Cells
Transfection of foam cells was performed using the
Lipofectamine
TM LTX Reagent (Invitrogen, USA) based on
the protocol recommended by the manufacturer (Invitrogen)
for the transfection of RAW264.7 macrophage cells with
minimal modiﬁcation.
On the day of transfection, growth medium from the
foam cells was replaced with 1 ml of fresh DMEM medium.
For each well of cells to be transfected, 0.6 μg of DNA was
diluted into 80 μl of Opti-MEM
® I Reduced Serum Medium
without serum. Then 0.75 μl PLUS
TM Reagent was added to
the diluted DNA and incubated for 5~15 min at room
temperature. For each well of cells, 1 μl of Lipofectamine
TM
LTX Reagent was added and incubated for 30 min at room
temperature to form DNA-Lipofectamine
TM LTX
complexes. After that, 80 μl of the DNA-Lipofectamine
TM
LTX complex was directly added to each well and they were
incubated at 37°C in a CO2 incubator for 24 h. The control
group foam cells were incubated under the same conditions
but were not transfected.
The cells were observed by light microscopy after
transfection. The efﬁciency of the transfection was ana-
lyzed by polymerase chain reaction (PCR) after CETP
genomic DNA was extracted using Genomic DNA Kit
(Tiangen Biotech). The PCR product was visualized by
agarose-gel electrophoresis and ethidium bromide statining
under UV light. Western blot was employed to analyze the
expression of CETP.
Phagocytosis Studies with Macrophages and Foam Cells
In Vitro Cell Viability Studies
Before the study of cellular uptake, the survived cells
were determined by MTT (3-(4, 5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) assay. In a 96-well plate, the
macrophage, transfected or untreated foam cells, were seeded
at a density of 10,000 cells per well in 0.2 ml of RPMI 1640
with 10% FBS, and then cultured at 37°C for 24 h. After
culture, the growth medium was replaced with fresh medium
containing LT-NLC or LT-NLC-apo at the concentration of 5,
10, 20, 40, and 80 μg/ml respectively. After 3 h, 20 μl of MTT
solution (5 mg/ml in phosphate buffer of pH 7.4, MTT Sigma,
Dorset, UK) was added to each well and incubated for
further 4 h. Then the medium was removed and formazan
crystals were solubilized with 200 μl of DMSO and the
absorbance was evaluated by a microplate reader (BIO-RAD
MODEL 680, USA) at 492 nm. All the experiments were
performed in triplicate. The relative cell viability (%) related
to control wells containing cell culture medium without
nanoparticles was calculated by
Relative viability % ðÞ ¼ A ½  test= A ½  control   100% ð2Þ
Phagocytosis Studies with Macrophages and Foam Cells
Three hours before the experiments, the medium was
replaced with 500 μl DMEM containing 5 mg/ml lipid-free
BSA and 4 mM β-mercaptoethanol. Experiments were
performed on three kinds of cells. (1) The macrophages were
incubated with either 16.5 μg/ml of LT-NLC-apo or LT-NLC.
(2) The foam cells were incubated with 16.5 μg/ml of LT-
NLC-apo and LT-NLC respectively. (3) The transfected foam
cells expressing CETP were incubated with the same concen-
tration as described before as well as 200 μl VLDL and
pancrelipase (80 mIU/mL).
After incubation at 37°C for 1, 2, and 3 h, the medium
was removed and cells were rinsed three times with Dulbec-
co's phosphate-buffered saline to remove the excessive non-
phagocytozed nanoparticles. Then the washed cells were
subjected to ﬁve freezing-thawing cycles to split the cells,
the drug in the cells was dissolved by adding 100 μlo f
methanol in each well. The lovastatin in the supernatant was
determined using the HPLC method described above. The
experiments were performed in triplicate.
Statistical Analysis
Statistically signiﬁcant differences were determined using
two-tailed Student's t test (SPSS, version 10.0). The p values
for signiﬁcance were set at 0.05 or 0.01.
RESULTS AND DISCUSSION
Preparation of LT-NLC and LT-NLC-apo
The optimization of LT-NLC formulation was based on
the entrapment efﬁciency and drug content. The preliminary
data established the most favorable weight ratio of cholesteryl
oleate, glycerol trioleate, soybean lecithin, and cholesterol as
30:13:50:6. Table I showed that the entrapment efﬁciency
reduced from 96.2±1.3% to 50.3±0.9% with the increase of
LT in the NLC from 5 to 20 mg. Therefore, 5 mg of LT was
chosen as the optimal dosage in the formulation in this study.
The high entrapment efﬁciency of the optimal LT-NLC
resulted from the high lipophilic nature of LT, which can be
easily incorporated into the apolar core of the LT-NLC.
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after incubation with native HDL, LT-NLC had acquired the
major apolipoprotein, apoA-I from thenative HDL and formed
rHDL nanoparticles (LT-NLC-apo) spontaneously (16). This
emphasizes the importance of the lipid portion of the particles,
as similar particle size and density of the NLC to HDL may
enable them bind to apoA-I speciﬁcally (28,29). The LT-NLC-
apo was used in the phagocytosis and targeting studies.
Characterization of LT-NLC and LT-NLC-apo
LT-NLC and LT-NLC-apo were characterized using PCS
and the size, zeta potential, and polydispersity index (PI) are
reported in Table II. The size of LT-NLC and LT-NLC-apo was
13.8±2.2 and 11.5±1.2 nm respectively, which was similar to
native HDL. The PIs were all below 0.5, but the LT-NLC-apo
showed more homogeneity (PI=0.11±0.05) than native HDL
(PI=0.21±0.06). The possible reason was that plasma HDLs are
highly heterogeneous lipoprotein particles which consist of
several subspecies with varying shape, density, size, and apolipo-
protein composition (30). But the LT-NLC-apo prepared in this
study was just one subclass of native HDL, spherical HDL.
The magnitude of zeta potential is an indication of the
repulsiveforcethatispresentinnanoparticlesandisakeyfactor
in predicting the long-term stability of colloidal dispersion
system (31). In general, particles can be dispersed stably when
the absolute value of zeta potential is above 30 mV due to the
electric repulsion between particles (32,33). As shown in
Table II, the surface charge of the different particles was
consistently negative. The average zeta potential of optimum
NLC was about −29.3±0.2 mV, indicating that the NLC
obtained in this study was a relatively dynamic stable system.
The negative charge in LT-NLC-apo (−18.7±0.5 mV) was less
than LT-NLC, suggesting that LT-NLC-apo was less stable than
LT-NLC in pH 8.0 buffer solution. The charge of native HDL
(−12.2±0.2 mV) was negative in pH 8.0 buffer solution because
it was above the isoelectric point of apolipoproteins.
Negative stain transmission electron microscopy (Fig. 1)
showed that a large portion of the optimized LT-NLC and LT-
NLC-apo particles were solid spherical or oval in shape with a
diameter of less than 20 nm, which was in agreement with the
diameter calculated from photon correlation spectroscopy
studies (Table II). However, most of the LT-NLC-apo
(Fig. 1b) appeared more regular than LT-NLC (Fig. 1a),
which may have resulted from the interaction of apoA-I
molecules and the NLC.
Characterization by DSC
DSC was employed to investigate the melting and
crystallization behavior of the crystalline material of lipid
nanoparticles. A sharp mel t i n gp e a ko fL Ta t1 7 3 . 8 ° C
(Fig. 2A) indicated its crystalline nature. The DSC thermal
behavior of the untreated lipid bulk was chosen as a
reference. Untreated mixtures (Fig. 2B) of phospholipids,
cholesteryl oleate, cholesterol, and glycerol trioleate showed
main transition peaks at 40.8°C, 54.5°C, and 253°C. The
presence of the melting peak of lovastatin in the physical
mixture (Fig. 2C) was 162°C, signifying that LT and other
components interacted with each other while heating. There
was no melting peak for LT in the lyophilized NLC (Fig. 2E)
or the SLN (Fig. 2D), suggesting that low amounts of the drug
in bulk lipid were not in the crystalline state but rather in a
dispersion state. During the preparation of SLN and NLC,
lipid and LT were dissolved in a mixture of solvents, and
subsequently solvents were evaporated, which allowed homo-
geneous dispersion of the drug in the lipid matrix (34).
Compared to SLN, the broadening of the transition peak
(phospholipids) and the reduction of the melting point
(cholesteryl oleate and phospholipids) of NLC indicated an
increased number of lattice defects (35) as a result of addition
of glycerol trioleate.
Storage and Stability of LT-NLC and LT-NLC-apo
To assess the effect of the storage temperature on
stability, the NLC dispersion was stored at 4°C and 25°C in
the dark over a period of 30 days (Table III). The LT-NLC
dispersion maintained excellent stability without exhibiting
any aggregation, precipitation, or phase separation at 4°C and
25°C for 1 month of storage. No signiﬁcant changes of
particle size or zeta potential were found over the storage
period at 4°C and 25°C. However, visible ﬂocculation of LT-
NLC-apo was found on the 21st day when stored at 4°C. The
poor stability of the LT-NLC-apo was probably due to the low
value of its zeta potential. The EE of the NLC was only
slightly decreased after 30 days.
Transfection of CETP into Foam Cells
Atherosclerosis is characterized by the accumulation of
lipids and ﬁbrous elements in the large arteries. The formation
of macrophage foam cells is an early sign of atherosclerotic
lesions. Furthermore, foam cells can affect the stability of a
plaque, potentially leading to its rupture and the threat of
coronarythrombosis(36,37).Thus, the establishmentof a stable
foam cell model is a signiﬁcant step for studies on atheroscle-
rosis. Exposure of RAW 264.7 cells, a murine macrophage cell
line, to ox-LDL for 24 h resulted in a marked accumulation of
intracellular cholesterol, indicated by Oil-Red O staining and
Table I. Effects of the Amount of LT on Entrapment Efﬁciency
(mean±SD, n=3)
LT(mg) Entrapment efﬁciency (%)
5 96.2±1.3
8 78.5±2.0
12 59.5±1.7
20 50.3±0.9
Table II. Particle Size, Polydispersity, and Zeta Potential of LT-NLC,
LT-NLC-apo, and Human Native HDL (mean±SD, n=3)
Samples Size (nm) PI Zeta potential (mV)
LT-NLC 13.8±2.2
a 0.21±0.06
b −29.3±0.2
b
LT-NLC-apo 11.5±1.2
a 0.11±0.05
b −18.7±0.5
b
Native HDL 9.5±1.1
a 0.47±0.10
b −12.2±0.2
b
PI polydispersity index
aNo signiﬁcant difference with native HDL (p>0.05)
bSigniﬁcant difference with native HDL (p<0.05)
1204 Gu et al.HPLC determination (data not shown), conﬁrming the forma-
tion of foam cells.
CETP, which is thought to mediate the exchange of HDL
cholesterol ester (CE) for triglyceride (TG) of TG-rich
lipoproteins (8), may play an important role in the prevention
of atherosclerosis. Since pure CETP is difﬁcult to obtain, we
prepared the foam cells expressing CETP by CETP plasmid
transfection.
Before transfection, the plasmid was ampliﬁed by trans-
formation into DH-5α E. coli cells. The concentration of the
puriﬁed plasmid was about 0.216 μg/ml. UV readings at 260/
280 nm consistently had ratios between 1.65 and 1.85 for all
the plasmid, indicating it was not contaminated with protein
or RNA (38).
The nucleofection protocol for the transfection of foam
cells provided by the manufacturer worked efﬁciently only
with RAW 264.7 macrophage cells. In this study, the protocol
was adopted with some modiﬁcation and has been success-
fully used in the transfection of CETP into foam cells. The
cells were examined using microscopy 24 h post-transfection
which showed normal cell morphology and no sign of
shrinkage. PCR and agarose-gel electrophoresis conﬁrmed
that CETP plasmids had been transfected into the foam cells.
Cytotoxicity Studies
Cytotoxicity analyses indicated that both LT-NLC and
LT-NLC-apo had little cytotoxic effects to cells and they
remained 95% in viable relative to control at the concen-
tration of 5, 10, 20, and 40 μg/ml. When the concentration
reached 80 μg/ml, both of them showed signiﬁcant loss in
viability of about 8–15%. The nanoparticles at 16.5 μg/ml
Fig. 1. TEM images of a LT-NLC and b LT-NLC-apo
Fig. 2. Overlaid differential scanning calorimetry curves of lovastatin (A), lipid mixtures of
phospholipids, cholesteryl oleate, cholesterol and glycerol trioleate (B), physical mixtures
of LT, phospholipids, cholesteryl oleate, and glycerol trioleate at a similar weight ratio to
LT-NLC formulation (C), lyophilized LT-SLN (D), and LT-NLC (E)
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the cells for the phagocytosis and targeting the study was
viable.
Uptake of LT in RAW 264.7 Macrophages
The rapid uptake of i.v. injected nanoparticles by cells of
the mononuclear phagocytic system (MPS) is a major obstacle
for a long blood circulation time and drug targeting to sites
other than the MPS (39). Avoidance of rapid clearance by the
MPS is a prerequisite for targeting nanocarriers to other
organs and tissues (40). In order to estimate if the NLC which
resembles the lipid components of HDL is able to avoid MPS
recognition in vivo, a trial was carried out on an in vitro
RAW264.7 macrophage model.
As shown in early experiments, LT-NLC can entrap
apolipoproteins effectively after incubation with native
HDL and form LT-NLC-apo which resembles the native
spherical HDL nanoparticle. From early studies of LDL,
VLDL, and aforementioned incubation studies, we can
infer that after i.v. injection LT-NLC may also be capable
to acquire the apolipoproteins presented in the blood-
stream (21). Thus, LT-NLC-apo could represent the
predominant component and be used for phagocytosis
and targeting studies in vitro.
LT-NLC and LT-NLC-apo were determined to be
stable in culture medium at 37°C for at least 3 h. As
s h o w ni nF i g .3, cellular uptake of LT-NLC (Fig. 3B)a n d
LT-NLC-apo (Fig. 3A) by macrophages proceeded rapidly
and approached the maximum at approximately 2 h. It is
notable that the uptake of LT-NLC was 2.2 times more
than LT-NLC-apo at 2 h and statistically distinguishable at
each experimental time point (p<0.01). This suggests that
after incubation with native HDL, LT-NLC turned to be
endogenous after coupling with apolipoproteins and this
reduced their recognition by macrophages. Also, the
uptake of both LT-NLC and LT-NLC-apo at 3 h was lower
than that at 2 h. This signiﬁes that uptake was saturated at
2h( 41) and macrophages which phagocytozed nano-
particles ﬂo a t e di nt h eD M E Ma f t e r3ha n dw e r ew a s h e d
away with buffer before analysis (12).
Foam Cell Targeting and Mechanism Study
To investigate the foam cell targeting property of LT-NLC-
apo, the foam cells were incubated with LT-NLC-apo (LT
16.5 μg/ml). The same concentration of LT-NLC was used as a
reference.Comparedtothedruguptakebymacrophage(Fig.3A
andB),uptakeofbothoftheLT-NLC-apo(Fig.3C)andL T -NLC
(Fig. 3D) by foam cells were increased signiﬁcantly (p<0.01).
Table III. The Stability Results of LT-NLC and LT-NLC-apo (mean±SD, n=3)
Storage time
(days)
Average size (nm) Zeta potential (mV)
EE of LT-NLC (%)
LT-NLC
(4°C) LT-NLC (25°C) LT-NLC-apo (4°C) LT-NLC (4°C) LT-NLC (25°C) LT-NLC-apo (4°C)
1 14.6±1.2 13.8±3.2 11.5±1.2 −29.3±0.2 −30.4±0.8 −18.7±0.5 96.2±1.3
7 14.9±1.3 14.5±2.8 36.3±5.7
a −30±1.2 −29.5±1.0 −12.3±2.2
a 95.4±1.1
14 15.4±1.0 17.3±1.9 76.3±13
a −28.7±1.1 −27±0.5 −10.5±3.8
a 93.2±1.8
21 15.2±1.8 17.8±1.7 255.8±13
a −26.3±1.9 −25.5±0.6 −5.7±1.1
a 93.0±0.9
30 17.3±1.6 18.4±3.6 – −26.8±1.7 −25±1.3 – 91.5±0.7
a
EE Entrapment efﬁciency
aSigniﬁcant difference with the ﬁrst day (p<0.05)
Fig. 3. Uptake of LT-NLC-apo and LT-NLC by RAW264.7 macrophages (A and B), foam cells (C and D) and foam cells
expressing CETP (E and F) with different incubation periods (n=3). (A and C): LT-NLC-apo; (B and D): LT-NLC; E:
LT-NLC-apo in the presence of VLDL and pancrelipase; F: LT-NLC in the presence of VLDL and pancrelipase. Results
(mean±SD, n=3) are expressed as the amount of LT phagocytozed with respect to 100,000 cells. Statistical signiﬁcances
(p<0.01) between : A and B; asterisk: C and D; and up-pointing triangle: E and F
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higher than LT-NLC (p<0.01). This is most probably due to
the presence of SR-BI receptors on the foam cells, which have
high afﬁnity for the LT-NLC-apo receptor (3,4).
To investigate whether the uptake of LT-NLC-apo could
be enhanced by the VLDL receptor pathway, TG-rich
lipoprotein (VLDL), and lipase with LT-NLC-apo were co-
incubated with CETP expressed foam cells. Figure 3E shows
that the amount of LT uptake by foam cells expressing CETP
increased signiﬁcantly (p< 0 . 0 1 )f o rL T - N L C - a p oi nt h e
presence of VLDL and lipase. In contrast, LT-NLC (the
control, Fig. 3F) showed no difference (p>0.05).
These results implied a receptor-mediated pathway by
CETP and VLDL involved in the targeting mechanism of LT-
NLC-apo to foam cells. In humans, the transport of HDL
cholesteryl esters from plasma to target cells involves a direct
uptake pathway, mediated by SR-BI, and an indirect pathway,
involving the exchange of HDL CE for triglycerides (TG) of
TG-rich lipoproteins (VLDL) by CETP, followed by hydrol-
ysis of TG by lipase (8). This raises the possibility that the
entry of the drug in the core into the VLDL might be
facilitated by the remodeling of HDL involving combined
activities of CETP and lipase. The VLDL can be bound to
VLDL receptors expressed in the foam cells (4), so the
uptake may be enhanced by the VLDL receptor pathway.
Hence it can be concluded that LT-NLC-apo is able to deliver
anti-atherogenic agents to foam cells effectively, and this
delivery can be enhanced by the VLDL receptor pathway.
CONCLUSIONS
In this paper, LT-NLC-apo resembling native HDL par-
ticles was prepared by incubating NLC cores with native HDL
and ultracentrifugation. LT-NLC-apo showed similar properties
to the native HDL with respect to size, shape, and composition.
Phagocytosis studies demonstrated that LT-NLC-apo had
turned endogenous and may be able to escape non-speciﬁc
recognition by macrophages. An in vitro study showed that LT-
NLC-apo, utilizing apoA-I asthepredominanttargeting moiety,
can deliver LT to foam cells through the VLDL receptor
pathway. This report provides early evidence that LT-NLC-apo
may be capable of delivering anti-atherogenic agents to foam
cells effectively for treatment of atherosclerosis. Further in vivo
studies on the targeting ability of this delivery system are
underway and will be reported in due course.
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